16 September 2026 editorial review · Item
Beta-cell regeneration / regrowth agents: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: DYRK1A/harmine papers concern human islet mass in mouse grafts, not demonstrated regeneration in living patients. Healthy-volunteer Phase 1 safety is not diabetes efficacy. Specificity, chronic proliferation and recurrent autoimmunity remain open.
- Registry NCT05526430: COMPLETED; updated 2025-01-16; enrollment 27 (ACTUAL); primary completion 2023-06-23 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: dom.12731; nm.3820; j.cmet.2018.12.005; scitranslmed.adg3456; s41586-019-0942-8; 02698811241273772.